Vidac Pharma offers a breakthrough new mode of action to treat cancer, targeting a common characteristic of cancer cells, reverting their abnormal metabolism. Vidac’s group of new chemical entities is based on a dominant IP portfolio of seven patent families. Its pipeline of novel therapies offers efficacy and tolerability to dermatologists, oncologists, and their patients.

First-in-Class Portfolio in Dermatology and Oncology